Lyfebulb-Helsinn
Innovation Summit &
Award In Oncology

Ten innovators will compete at the Lyfebulb-Helsinn Investment Fund Innovation Summit for the first ever Lyfebulb-Helsinn Investment Fund Innovation Award, which will be presented to an exceptional innovator with outstanding entrepreneurial potential to commercialize creative efforts and ideas to better manage cancer using drugs, medical devices, or consumer products, and healthcare information technologies


MARCH 26-27, 2018 | MONTE-CARLO BAY HOTEL & RESORT, MONACO

Deadline for applications is January 22, 2018

The Award

One innovator will be awarded the first Lyfebulb-Helsinn Investment Fund Innovation Award in cancer treatment and cancer supportive care


ABOUT THE AWARD

Monetary grants up to $50K will be awarded to the winners, as well as the opportunity for all finalists to be in a position to be better noticed by venture capital funds

BENEFITS OF THE LYFEBULB-HELSINN INVESTMENT FUND INNOVATION SUMMIT & AWARD

National and international recognition. The benefit for innovators of participating is
the visibility given to the selected 10 finalists,and the Winner in particular

Invitation to the Lyfebulb–Helsinn Innovation Summit 2018 in Monaco as one of 10 Finalists.
The Innovation Summit aims to link innovators with senior leadership from Lyfebulb and Helsinn in order
to spotlight innovators’ efforts and ideas, and provide professional discussion, direction, and inspiration.

The winner will be chosen on March 27, 2018 by a prestigious, international panel

APPLY NOW

THE SUMMIT

At this Summit, 10 selected Innovators will compete for
monetary grants and be given the opportunity to be considered for a
possible investment by the Helsinn Investment Fund


ABOUT THE SUMMIT

 

MARCH 26-27, 2018 | MONTE-CARLO BAY HOTEL & RESORT, MONACO

Beyond presenting their innovative ventures to this group, the 10 finalists will also have a chance to interact and exchange ideas on how to advance further patient innovatorship in the cancer community, engage with Lyfebulb founders, Helsinn Investment Fund leadership, representatives from the patient community, key opinion leaders, and potential investors and compete for a monetary grant

The Lyfebulb-Helsinn Investment Fund Innovation Summit stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features people who have created a product and a company based on issues encountered because of their personal experiences with a chronic illness

Patient innovators have a unique ability to create a value-adding disease intervention beyond therapy. Our aim is to support patient-driven innovation and we are laser-focused on improving the quality of life for those living with cancer

AWARD & JUDGING CRITERIA

The Award is open to innovators currently working on an
groundbreaking project, which can advance the prevention, management, or
care of cancer. The Award is open to innovators focused on the better
management of cancer using drugs, medical devices, or consumer
products, and healthcare information technologies


WHAT ARE THE JUDGING CRITERIA?

The judging panel will look for evidence of:

  • How does the invention/product have the potential to improve the lives of people with cancer?
  • How is the product or service unique in the market (not an altered marketed product) and meets other demands as well?
  • Usage of innovative and effective technologies that are scalable
  • Ability to meet most of the healthcare challenges (e.g. funding, regulations, requirements for clinical testing, etc.)

SUMMIT AGENDA

March 26, 2018: Morning
Arrival
March 26, 2018: Afternoon
Peer-to-peer meet-ups
March 26, 2018: Evening
Informal dinner
March 27, 2018: Morning
Plenary “pitch” session: presentations
March 27, 2018: Mid-Morning
Standing lunch for participants and jury
March 27, 2018: Afternoon
Afternoon workshops & Plenary session
March 27, 2018: Evening
Gala dinner & Award winner announcement

APPLY FOR THE LYFEBULB-HELSINN INNOVATION AWARD

Deadline for applications is January 22, 2018



  • FacebookTwitterLinkedinOther 
    Add a new row
  • Describe your estbalished company for developing and commercializing your idea? (Please give evidence of registration)
  • What is your personal connection with Cancer?
  • A Patient Entrepreneur is someone who is living with, or is affected by a chronic disease (i.e: relative or loved one) and is working on an innovative project to better the management of those living with that chronic disease. Please do not include any personal information about the management of cancer.)
  • Explain the problem your innovative idea or concept aims to solve.
  • If awarded the Lyfebulb-Helsinn Investment Fund Innovation Award and monetary prize please describe how you plan to further the advancement of your idea?*
  • Guidance for the PDF

    Please attach a 2-page (maximum) non-confidential Executive Summary of your business:

    - Your story and describe your idea
    - Technical explanation of the concept, including an explanation of the technical feasibility.
    - Evidence of how you have you used innovative and effective technologies to scale up your idea
    - Examples of how you have overcome healthcare related challenges in developing your ideas.
    - Business plans, including development and commercial plans, as well as the team behind the project, patent status, funding raised for the project.
  • Accepted file types: pdf.
  • Please upload a short video (less than five minutes) showcasing your idea and explaining the problem and how it has the potential to help other people living with cancer.
  • Please upload a high resolution profile picture (at least 800px x 800px)
  • Lyfebulb Innovation Award Terms and Conditions

    Conditions to Apply

    In order to apply for the Lyfebulb Innovation Award and the Innovation Summit, applicant must fulfil all the bellow conditions:

    (a) The applicant must be working on innovative ideas and concepts for better management of cancer using consumer or medical devices, or healthcare IT.

    (b) The applicant is a cancer survivor or has a close family member and/or loved one living with cancer.

    (c) The applicant must have established a registered company for developing and commercializing his or her idea, concept, product or service.

    (d) The applicant’s idea, concept, product or service must be original and not include altered or copied products from third parties.

    (e) The applicant's idea, concept, product or services must, to the applicant's knowledge, be free of third party rights, including intellectual property rights.

    (f) Applicant must be 18 years of age or older.

    (g) Participants will be required to sign an agreement with Helsinn Investment Fund to ensure compliance with Helsinn Investment Fund policies.

    U.S. Applicants

    Patients participating in any U.S. government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, are not eligible to participate. This includes patients participating in a Managed Medicaid plan or who have Medicaid as secondary insurance.

    No Referral or Product Use Requirement. Application imposes no referral or Helsinn product or service use requirement.

    Personal Data. By submitting an application for the Lyfebulb Innovation Award and the Innovation Summit, applicant expressly consents to: (i) the collection, use and retention by Lyfebulb and Helsinn Investment Fund of the applicant’s personal and business information contained in the application for all purposes (including promotion and publicity) related to the Lyfebulb Innovation Award and the Innovation Summit; and (ii) the publication of the applicant’s name and entrepreneurial story on Lyfebulb’s and Helsinn Investment Fund’s’s websites as well as on their social media channels (Facebook, Twitter, YouTube, Instagram, etc.). Any such information submitted will be transferred to servers located in the United States of America and treated under the laws of the United States of America.

Achieving More, Together

Lyfebulb

Lyfebulb is a business focused on bringing innovative products and solutions focused on chronic disease to market. Lyfebulb serves as a bridge between patients and industry, and its mission is to improve the quality of life of those living with chronic disease.

Helsinn Investment Fund

The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients

Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions

For more information, visit www.helsinninvestmentfund.com